Medical Device Risk Assessment
Physician and biomedical-engineer-led scoring across 510(k), De Novo, and PMA pathways. Predicate integrity, cybersecurity, manufacturing QMS, and reimbursement risk — in 24–48 hours.
The Problem
Predicate devices get pulled. Cybersecurity becomes a submission block. Manufacturing audits surface CAPAs the seller never disclosed. Reimbursement is assumed, not verified. Vantage finds these in days, not after close.
Your target's 510(k) cites a predicate that's been recalled or subject to Class I action. FDA won't let you ride that predicate forward.
Post-Oct 2023, FDA refuses to accept submissions without SBOM + threat model. Many sellers still haven't caught up.
CAPA backlog, unresolved 483 observations, supplier-qualification gaps that don't show up in the data room.
"It's a 510(k), so it's reimbursed" is false. CPT/HCPCS coverage varies by payer, site of service, and procedure bundling.
P&T committee rejection, IDN procurement blocks, physician workflow mismatch — not found in the regulatory file.
Legacy CE-marked devices losing MDR extension are a hidden revenue cliff most US buyers miss.
Regulatory Pathways We Cover
The risk profile for a 510(k) is nothing like a PMA. De Novo sits in between with its own traps. Our model weights evidence and outcomes per pathway, not one-size-fits-all.
Most common pathway. Biggest pitfalls: predicate integrity, split predicates, technological characteristics creep, and clinical performance data adequacy.
Used when no valid predicate exists. Risk is acceptance of special controls, post-market requirements, and reclassification implications for future entrants.
Highest-risk Class III devices. Panel meetings, clinical trial integrity, QSR inspection, and CE-mark strategy dominate the risk profile.
Device-Specific Index Weighting
Same 20-category taxonomy as every vertical. The weights reflect what actually kills device deals. Percentage shown is relative contribution to the composite Vantage Index.
| Domain | Weight | What we're looking at |
|---|---|---|
| Regulatory Pathway Integrity | Predicate validity, pathway choice, FDA correspondence, 510(k) summary quality, indications-for-use drift | |
| Clinical Evidence & Adoption | Pivotal trial design, endpoint validity, real-world evidence, P&T committee history, KOL adoption | |
| Reimbursement & Coding | CPT/HCPCS coverage, CMS NCD/LCD, payer policies, site-of-service bundling, prior auth burden | |
| Manufacturing & QMS | 483 history, CAPA backlog, supplier controls, design history file completeness, QSR/21 CFR 820 gaps | |
| Cybersecurity & Postmarket | SBOM completeness, threat model, postmarket update plan, 524B readiness, recall and MAUDE history | |
| IP & Freedom-to-Operate | Patent thicket analysis, FTO opinions, design-around risk, trade-secret posture, licensing obligations | |
| Commercial & Market Access | IDN contract landscape, GPO alignment, sales model, TAM rigor, competitor launch history | |
| Financial & Operational | Burn rate, unit economics, inventory, supply continuity, exit track record — provided by buy-side |
Pricing Ladder
Start with a Quick Screen to triage. Scale up to a full report when the deal moves. Every tier returns in 24–72 hours with named physician + engineer reviewers.
Want continuous monitoring post-close? Surveillance from $1,500/mo →
Device Intelligence Library
Deep dives on the specific device risks that cost investors and acquirers real money. Written by Arvind and Aswini.
A recalled predicate doesn't just embarrass the seller — it can retroactively invalidate the clearance and force a new submission.
Read → CybersecuritySBOM, threat model, postmarket update plan. What FDA refuses to accept, and how to assess whether your target is ready.
Read → CommercialClearance is the starting line, not the finish. P&T committees, IDN procurement, and reimbursement coding kill more launches than FDA does.
Read → Pathway StrategyDe Novo looks slower and costlier — but the strategic moat it creates can be worth the 12 extra months. How to evaluate the choice.
Read → RegulatoryNew performance testing expectations, clinical data thresholds, and predicate scrutiny. What seasoned reg-affairs teams are still missing.
Read → QMS483 trends, CAPA aging, supplier-qualification gaps, design-history-file hygiene. What a real QMS diligence looks like.
Read →Send us the target and a data-room link (or even just a 510(k) number). We return a Quick Screen in 24 hours. If you want to start with a call first, we'll make time today.